Therapeutic targeting of respiratory syncytial virus G-protein

Immunotherapy

Volumn 2, Issue 5, 2010, Pages 655-661

  Kauvar, Lawrence M ^a   Harcourt, Jennifer L ^b   Haynes, Lia M ^b   Tripp, Ralph A ^c  

^a Trellis Bioscience   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

antibody therapy; innate immunity; prophylaxis; RSV; therapeutics; treatment

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; MONOCLONAL ANTIBODY; MOTAVIZUMAB; PALIVIZUMAB;

BRONCHIOLITIS; CHILD CARE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PNEUMONIA; PNEUMOVIRUS INFECTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; GTP-BINDING PROTEINS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; IMMUNOTHERAPY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK; VIRAL PROTEINS;

EID: 77957555834     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.53     Document Type: Review

References (51)

1. Hall CB, Weinberg GA, Iwane MK et al.: The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360(6), 588-598 (2009). □ Major epidemiology study that has defined the unmet pediatric clinical need.
2. Centers for Disease Control and Prevention (CDC): Respiratory syncytial virus activity - United States, July 2008-December 2009. MMWR Morb. Mortal. Wkly Rep. 59(8), 230-233 (2009).
3. Oshansky CM, Zhang W, Moore E, Tripp RA: The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 4, 279-297 (2009).
4. Mejias A, Chavez-Bueno S, Gomez AM et al.: Respiratory syncytial virus persistence: evidence in the mouse model. Pediatr. Infect. Dis. J. 27 (10 Suppl.), S60-S62 (2008).
5. Mohapatra SS, Boyapalle S: Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin. Microbiol. Rev. 21(3), 495-504 (2008).
6. Thomsen SF, van der Sluis S, Stensballe LG et al.: Exploring the association between severe respiratory syncytial virus infection and asthma: a registry-based twin study. Am. J. Respir. Crit. Care Med. 179(12), 1091-1097 (2009).
7. Simoes EA, Groothuis JR, Carbonell-Estrany X et al.: Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr. 151(1), 34-42, 42, E31 (2007).
8. Empey KM, Peebles RS, Jr, Kolls JK: Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin. Infect. Dis. 50(9), 1258-1267 (2010).
9. Somers CC, Ahmad N, Mejias A et al.: Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial. Pediatr. Allergy Immunol. 20(5), 477-485 (2009).
10. Power UF: Respiratory syncytial virus (RSV) vaccines - two steps back for one leap forward. J. Clin. Virol. 41(1), 38-44 (2008).
11. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ: CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2(8), 732-738 (2001).
12. Zhang W, Choi Y, Haynes L et al.: Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J. Virol. 84(2), 1148-1157 (2010).
13. Haynes LM, Caidi H, Radu GU et al.: Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J. Infect. Dis. 200(3), 439-447 (2009).
14. Collarini EJ, Lee FE, Foord O et al.: Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J. Immunol. 183(10), 6338-6345 (2009). □ A 1 pM affinity antibody to respiratory syncytial virus (RSV) G-protein was isolated from human B cells of recovering patients, providing a promising candidate for a new therapeutic agent.
15. Cowton VM, McGivern DR, Fearns R: Unravelling the complexities of respiratory syncytial virus RNA synthesis. J. Gen. Virol. 87 (Pt 7), 1805-1821 (2006).
16. Collins PL, Murphy BR: New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc. Am. Thorac. Soc. 2(2), 166-173 (2005).
17. Rawling J, Melero JA: The use of monoclonal antibodies and lectins to identify changes in viral glycoproteins that are influenced by glycosylation: the case of human respiratory syncytial virus attachment (G) glycoprotein. Methods Mol. Biol. 379, 109-125 (2007).
18. Pichavant M, Goya S, Hamelmann E, Gelfand EW, Umetsu DT: Animal models of airway sensitization. Curr. Protoc. Immunol. Chapter 15, Unit 15, 18 (2007).
19. Wegmann M: Th2 cells as targets for therapeutic intervention in allergic bronchial asthma. Expert Rev. Mol. Diagn. 9(1), 85-100 (2009).
20. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO: Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am. J. Respir. Crit. Care Med. 168(6), 633-639 (2003).
21. Reed JL, Brewah YA, Delaney T et al.: Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J. Infect. Dis. 198(12), 1783-1793 (2008). □ Comparison of lung histopathology between fatal cases of RSV in infants on the one hand and mice with impaired macrophages and on the other hand highlighted the importance of the innate immune response to the clinical pathology associated with RSV.
22. Becker Y: Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy - a review. Virus Genes 33(2), 235-252 (2006).
23. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS: Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72(4), 2871-2880 (1998).
24. Maher CF, Hussell T, Blair E, Ring CJ, Openshaw PJ: Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect. 6(12), 1049-1055 (2004).
25. Bukreyev A, Yang L, Fricke J et al.: The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82(24), 12191-12204 (2008). □ High level of soluble G-protein was shown to reduce the efficacy of antibodies to both the F-and G-proteins, indicating a deeper role in modulation of the host immune response than can be accounted for simply by acting as a sponge for anti-G antibodies.
26. Castilow EM, Olson MR, Varga SM: Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res. 39(1-3), 225-239 (2007).
27. Oshansky CM, Krunkosky TM, Barber J, Jones LP, Tripp RA: Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol. 22(3), 147-161 (2009). □ Mechanisms by which the RSV G-protein suppresses an effective host immune response include distortion of the innate immune response.
28. Shingai M, Azuma M, Ebihara T et al.: Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction. Int. Immunol. 20(9), 1169-1180 (2008).
29. Gonzalez PA, Prado CE, Leiva ED et al.: Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc. Natl Acad. Sci. USA 105(39), 14999-15004 (2008). □ RSV subversion of the host immune response acts at several levels, including interference with T-cell activation by infected dendritic cells.
30. Monick MM, Yarovinsky TO, Powers LS et al.: Respiratory syncytial virus upregulates TLR4 and sensitizes airway epithelial cells to endotoxin. J. Biol. Chem. 278(52), 53035-53044 (2003).
31. Polack FP, Irusta PM, Hoffman SJ et al.: The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc. Natl Acad. Sci. USA 102(25), 8996-9001 (2005).
32. Dalpke A, Heeg K, Bartz H, Baetz A: Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins. Immunobiology 213(3-4), 225-235 (2008).
33. Umehara H, Bloom E, Okazaki T, Domae N, Imai T: Fractalkine and vascular injury. Trends Immunol. 22(11), 602-607 (2001).
34. Tripp RA, Oshansky C, Alvarez R: Cytokines and respiratory syncytial virus infection. Proc. Am. Thorac. Soc. 2(2), 147-149 (2005).
35. Amanatidou V, Sourvinos G, Apostolakis S, Tsilimigaki A, Spandidos DA: T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatr. Infect. Dis. J. 25(5), 410-414 (2006).
36. Tal G, Mandelberg A, Dalal I et al.: Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J. Infect. Dis. 189(11), 2057-2063 (2004).
37. Mailaparambil B, Krueger M, Heinze J, Forster J, Heinzmann A: Polymorphisms of Toll like receptors in the genetics of severe RSV associated diseases. Dis. Markers 25(1), 59-65 (2008).
38. Miyairi I, De Vincenzo JP: Human genetic factors and respiratory syncytial virus disease severity. Clin. Microbiol. Rev. 21(4), 686-703 (2008). □ Two genetic polymorphisms that affect known targets of the RSV G-protein are among the epidemiological risk factors for severe RSV disease.
39. Plotnicky-Gilquin H, Cyblat-Chanal D, Goetsch L et al.: Passive transfer of serum antibodies induced by BBG2Na, a subunit vaccine, in the elderly protects SCID mouse lungs against respiratory syncytial virus challenge. Virology 303(1), 130-137 (2002).
40. + T cell responses. J. Immunol. 176(3), 1600-1608 (2006).
41. Ramilo O: Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules. Paediatr. Respir. Rev. 10 (Suppl. 1), 23-25 (2009).
42. Carbonell-Estrany X, Simoes EA, Dagan R et al.: Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125(1), E35-E51 (2010).
43. Wu H, Pfarr DS, Johnson S et al.: Development of motavizumab, an ultrapotent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368(3), 652-665 (2007).
44. Gill MA, Welliver RC: Motavizumab for the prevention of respiratory syncytial virus infection in infants. Expert Opin. Biol. Ther. 9(10), 1335-1345 (2009).
45. Georgescu G, Chemaly RF: Palivizumab: where to from here? Expert Opin. Biol. Ther. 9(1), 139-147 (2009).
46. Lagos R, De Vincenzo JP, Munoz A et al.: Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr. Infect. Dis. J. 28(9), 835-837 (2009).
47. Taylor G, Stott EJ, Bew M et al.: Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52(1), 137-142 (1984).
48. Walsh EE, Hall CB, Schlesinger JJ, Brandriss MW, Hildreth S, Paradiso P: Comparison of antigenic sites of subtypespecific respiratory syncytial virus attachment proteins. J. Gen. Virol. 70 (Pt 11), 2953-2961 (1989).
49. Miao C, Radu GU, Caidi H, Tripp RA, Anderson LJ, Haynes LM: Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F (ab') 2 components mediates reduced pulmonary inflammation in mice. J. Gen. Virol. 90 (Pt 5), 1119-1123 (2009). □ Clear distinction between direct antiviral activity of a monoclonal antibody against RSV G-protein and the effect on airway inflammation was established by molecular dissection of the antibody.
50. Mekseepralard C, Toms GL, Routledge EG: Protection of mice against human respiratory syncytial virus by wild-type and aglycosyl mouse-human chimaeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein. J. Gen. Virol. 87 (Pt 5), 1267-1273 (2006).
51. Borek AP, Clemens SH, Gaskins VK, Aird DZ, Valsamakis A: Respiratory syncytial virus detection by Remel Xpect, Binax Now RSV, direct immunofluorescent staining, and tissue culture. J. Clin. Microbiol 44(3), 1105-1107 (2006).